Over the last 25 years, our research has focused on identifying molecular vulnerabilities in cancer cells and abnormal immune cells that can be targeted with novel and innovative therapeutics.
This research led to the identification of novel drug targets that now form the basis of an innovative pipeline with value-based, first-in-class medications that are scalable to address global unmet medical needs for cancer and inflammatory diseases.
CV6 Therapeutics was founded in 2013 to accelerate the development of these novel targeted small molecule therapeutics. CV6 Therapeutics’ first oncology drug, CV6-168, is currently in a Phase 1a clinical trial. More information on the Phase 1a trial can be viewed here: CV6-168 Phase 1a
